EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups

Marina Caballero-Bellón, Mari Wilhelmsson, Jonathan D Wasserman, Tara McKeown, Derek S Tsang, Uri Tabori, Annie Huang, Anthony P Y Liu, Anirban Das, Julie Bennett, Ute Bartels, Eric Bouffet und 1 weitere

Neuro-Oncology Pediatrics · 2025

DOI: 10.1093/neuped/wuaf006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, 2025. Verfasst von Marina Caballero-Bellón und 12 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meagan Bebenek Fellowship.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment for medulloblastoma can lead to significant long-term endocrine sequelae, including growth hormone (GH) deficiency. There has been some concern that GH replacement can increase the risk of tumor relapse. Our goal was to assess the risk of recurrence after GH therapy in medulloblastoma (MB) patients treated with ­modern, molecularly informed protocols.

Methods

We conducted a retrospective observational cohort study at a tertiary pediatric hospital from January 1999 to December 2022. Patients < 18 years old with MB who received craniospinal irradiation (CSI) were included, treated according to contemporary risk-adapted protocols. Epidemiological, molecular, and clinical data were collected.

Results

A total of 148 patients with MB were treated with CSI, with a median age of 8.3 years (IQR 5.9-10.8). The molecular subgroups included Group 4 (n = 69, 46.6%), Group 3 (n = 27, 18.2%), WNT (n = 21, 14.2%), and SHH (n = 20, 13.5%). During follow-up, 79 patients (53.4%) were diagnosed with GH deficiency, and 73 of them initiated GH therapy. We found no association between sex (P = 1), presence of metastases (P = .14), or molecular subgroup (P = .71) and the use of GH therapy. Thirty-four patients (22.9%) relapsed during follow-up, with 10 of them receiving GH therapy (13.7% of all patients on GH). Progression-free survival (PFS) was higher among those who received GH replacement therapy, even within each subgroup independently. In a multivariate analysis of patients who had not relapsed at least 2 years post-diagnosis, GH replacement was associated with significantly improved overall survival (OS) and a trend toward improved PFS (PFS: HR 0.35, 95% CI, 0.12-1.08, P = .068; OS: HR 0.34, 95% CI, 0.12-0.99, P = .049).

Conclusions

The use of GH is not associated with an increased risk of recurrence or death in children with medulloblastoma treated with CSI according to current protocols. Our results provide further reassurance that all children with requiring treatment for growth hormone deficiency after medulloblastoma therapy should be offered physiological growth hormone replacement.

Förderung

  • Meagan Bebenek Fellowship

Zitieren

APA

Caballero-Bellón, M., Wilhelmsson, M., Wasserman, J. D., McKeown, T., Tsang, D. S., Tabori, U., Huang, A., Liu, A. P. Y., Das, A., Bennett, J., Bartels, U., Bouffet, E., & Ramaswamy, V. (2025). Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuaf006

Vancouver

Caballero-Bellón M, Wilhelmsson M, Wasserman JD, McKeown T, Tsang DS, Tabori U, et al. Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups. Neuro-Oncology Pediatrics. 2025. doi:10.1093/neuped/wuaf006

BibTeX
@article{CaballeroBelln2025,
  author = {Caballero-Bellón, Marina and Wilhelmsson, Mari and Wasserman, Jonathan D and McKeown, Tara and Tsang, Derek S and Tabori, Uri and Huang, Annie and Liu, Anthony P Y and Das, Anirban and Bennett, Julie and Bartels, Ute and Bouffet, Eric and Ramaswamy, Vijay},
  title = {Growth hormone replacement therapy does not predict relapse across medulloblastoma subgroups},
  journal = {Neuro-Oncology Pediatrics},
  year = {2025},
  doi = {10.1093/neuped/wuaf006}
}
Kostenlos starten →